{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T10:14:02Z","timestamp":1694859242071},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"14","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There has been a significant improvement in both our understanding and therapeutic choices available to clinicians for the management of cancer associated thrombosis (CAT). Even with the recent publication of a systematic review and landmark trials demonstrating the non-inferiority of DOACS-based anticoagulation strategy compared to the standard of care in patients with CAT, there is unresolved uncertainty regarding the exact hierarchy of risks and effectiveness of various DOAC analogues in these cohorts of patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method:<\/jats:title>\n            <jats:p>We will carry out a network meta-analyses, utilizing a novel generalized pairwise methodology to generate direct and indirect comparisons between the various DOAC analogues. We will search the following databases for studies that satisfies pre-specified inclusions criteria; these include PubMed, EMBASE, Cochrane library, Clinicaltrials.gov, conference abstracts among other sources. The primary efficacy and safety outcomes are recurrent VTE and major hemorrhagic events, respectively. Two reviewers will Search the databases independently with the view to identify studies that meet eligibility criteria. The methodological quality of the included studies will be determined using a recently validated risk of bias assessment tool.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We expect that the result of this review will ascertain the hierarchy of risks and effectiveness of various DOAC analogues in patients with CAT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Results of this review will assist in informed decisions making regarding therapeutic guidelines of DOAC in CAT.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000019679","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T08:44:34Z","timestamp":1585817074000},"page":"e19679","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness and safety of direct-acting oral anticoagulants (DOACS) for the reduction of recurrent venous thromboembolism in cancer patients"],"prefix":"10.1097","volume":"99","author":[{"given":"Mohammed ibn-Mas\u2019ud","family":"Danjuma","sequence":"first","affiliation":[{"name":"Qatar University, College of Medicine, QU, Health, Doha"},{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mouhand F.H.","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamad Nabil","family":"ElShafei","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haajra","family":"Fatima","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaikha Al","family":"Shokri","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Yusuf","family":"Abubeker","sequence":"additional","affiliation":[{"name":"Rochester regional health Unity Internal Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anand","family":"Kartha","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdel-Naser","family":"Elzouki","sequence":"additional","affiliation":[{"name":"Qatar University, College of Medicine, QU, Health, Doha"},{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Gaafar Hussein","family":"Mohamedali","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hamad General hospital, Hamad Medical Corporation, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Mahgboub","sequence":"additional","affiliation":[{"name":"Wirral University Hospital, NHS foundation Trust, Wirral, Liverpool, UK."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mubarak","family":"Bidmos","sequence":"additional","affiliation":[{"name":"Qatar University, College of Medicine, QU, Health, Doha"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/5584_2016_111","article-title":"The treatment of venous thromboembolism in patients with cancer","volume":"906","author":"Prandoni","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.9243","article-title":"Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial","volume":"314","author":"Lee","year":"2015","journal-title":"JAMA"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"Carrier","year":"2018","journal-title":"Curr Oncol"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1536\/ihj.16-482","article-title":"Comparison of direct oral anticoagulants and warfarin in the treatment of deep venous thrombosis in the chronic phase","volume":"59","author":"Wakakura","year":"2018","journal-title":"Int Heart J"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3389\/fphar.2019.00773","article-title":"Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer-associated thrombosis: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies","volume":"10","author":"Wang","year":"2019","journal-title":"Front Pharmacol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.12.016","article-title":"Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis","volume":"150","author":"Ross","year":"2017","journal-title":"Thromb Res"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1160\/TH14-11-0977","article-title":"Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer","volume":"114","author":"Schulman","year":"2015","journal-title":"Thromb Haemost"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"R13-20230915","doi-asserted-by":"crossref","DOI":"10.1097\/XEB.0000000000000165","article-title":"A unified framework for bias assessment in clinical research","author":"Stone","year":"2019","journal-title":"Int J Evid Based Healthc"},{"key":"R14-20230915","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/XEB.0000000000000140","article-title":"A generalized pairwise modelling framework for network meta-analysis","volume":"16","author":"Doi","year":"2018","journal-title":"Int J Evid Based Healthc"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019679","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T22:18:02Z","timestamp":1694816282000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000019679"}},"subtitle":["A protocol for systematic review and network meta-analysis using a generalized pairwise modeling methodology"],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":15,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000019679","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}